UBS O'Connor’s Dyne Therapeutics DYN Stock Holding History

UBS O'Connor’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,000	Closed	-$49K	–	377
2024 Q4	$49K	Buy	+20,000	New	+$592K	﹤0.01%	367

Other funds holding DYN

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's DYN Position: Q2 2025 in Review

UBS O'Connor sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 21,422 shares — an estimated $224K sold.

UBS O'Connor first reported a position in DYN in Q1 2022 and held it in 13 quarters. The position peaked at $2.41M in Q4 2022. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

UBS O'Connor reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
UBS O'Connor sold 21,422 Dyne Therapeutics shares in Q2 2025, an estimated $224K.
UBS O'Connor first reported a position in Dyne Therapeutics in Q1 2022 and held it in 13 quarters.
UBS O'Connor's Dyne Therapeutics position peaked at $2.41M in Q4 2022.
197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.